Abcam, ab258779, Human ADPGK knockout HEK-293T cell lysate

Size: 1Kit
ADPGK KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 25 bp deletion in exon1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 25 bp deletion in exon1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ADPGK, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ADP-dependent glucokinase commonly known as ADPGK is an enzyme that catalyzes the phosphorylation of glucose. ADPGK has a molecular mass of approximately 53 kDa. This protein primarily expresses in various tissues including liver and heart where it participates in glycolytic processes. The enzyme functions under anaerobic conditions facilitating glucose utilization when oxygen levels are low.
Biological function summary
ADPGK facilitates energy production in cells by converting glucose into glucose-6-phosphate. This conversion is part of cellular energy metabolism especially in conditions with limited oxygen supply. While ADPGK generally acts independently under certain conditions it may interact with glucose transporters to optimize glucose uptake and metabolism. Its role is pivotal in enabling cells to adapt to metabolic demands by promoting glycolysis even without oxygen.
Pathways
ADPGK acts within the glycolytic pathway a central metabolic pathway that provides energy and biosynthetic precursors. It works alongside enzymes like hexokinase indicating a functional relationship in glycolysis initiation. ADPGK is also linked to the pentose phosphate pathway indirectly influencing NADPH production and ribose synthesis. These pathways interplay to balance energy production and anabolic reactions highlighting ADPGK's significance in cellular metabolism.
ADPGK influences conditions associated with impaired energy metabolism. Notably its altered function associates with certain types of cancer where abnormal glycolysis often called the Warburg effect occurs. ADPGK has connections to glucose transporters and hexokinase in these contexts impacting cancer cell metabolism. It also shows relevance in metabolic syndromes where altered glucose processing leads to various health complications. Understanding ADPGK functions helps in targeting these pathways for therapeutic interventions.